Navigation Links
Study compares strategies for BK virus nephropathy
Date:11/26/2008

For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN), promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney (graft loss), according to a report in the November Clinical Journal of the American Society of Nephrology (CJASN).

"Our study is the first that demonstrates differences in outcomes when comparing two different immunosuppression tapering approaches in BKVAN, an increasingly prevalent, discouraging problem after kidney transplantation," comments Alexander C.Wiseman, MD, of the University of Colorado at Denver Health Sciences Center, one of the study authors.

The researchers compared the results of competing strategies for reducing immunosuppressive therapy in kidney transplant recipients with BKVAN. "Recognized slightly more than 10 years ago, BKVAN is caused by reactivation of a virus that exists latent in about 80 percent of all human kidneys," explains Dr. Wiseman. In healthy people, the BK virus is harmless.

However, in patients receiving immunosuppressive drugs to prevent rejection after kidney transplantation, the BK virus can become reactivated. "BKVAN occurs in two to 10 percent of kidney transplant recipients, routinely causing irreversible graft injury with a high frequency of graft loss," says Dr. Wiseman.

Of 910 patients receiving kidney transplants between 1999 and 2005, 3.8 percent developed BKVAN. Of these, 46 percent eventually lost the transplanted kidney. One group of patients was treated using a "withdrawal" strategy, in which the number of immunosuppressive drugs was cut back from three to two. Another group was treated by a "reduction" strategy, with a reduced dose of all three medications. The idea is that cutting back on anti-rejection drugs will allow the body's immune system to become strong enough to fight off the BK virus.

One year later, the transplanted kidney was still functioning in 88 percent of patients treated by the "withdrawal" strategy, compared to 56 percent with the "reduction" strategy. Early withdrawal of immunosuppressive drugswithin one month after the diagnosis of BKVANreduced the risk of graft loss by two-thirds.

Another treatment, called depleting antibody induction, was associated with a fourfold increase in the risk of graft loss. All of the treatment differences remained significant after adjustment for other factors.

Outcomes were much better when BKVAN was managed by specialists at the transplant center. For these patients, the risk of graft loss was eleven times lower than for patients managed by the patient's home nephrologist, in cooperation with the transplant center. This may have partially reflected the large number of patients from rural areas, drawn from five Western states, treated at the University of Colorado transplant center.

The results highlight the need for increased awareness and early diagnosis of BKVAN, with "aggressive tapering of immunosuppression" as soon as the diagnosis is made, according to Dr. Wiseman. "Our study also identifies a potential need for the general nephrology community to adopt screening strategies for BKVAN, and to understand the prevalence and severity of the disease outside the transplant center." Dr. Wiseman also notes some limitations of the study, including the fact that it was retrospective in nature and did not include a large percentage of black patients.


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Study: Childhood constipation just as serious as asthma
2. Stanford/Packard study shows no benefit from drug widely used to prevent premature births
3. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
4. Study: Want to be happier? Be more grateful
5. Study Calls for Greater Scrutiny of Off-Label Drug Use
6. Study suggests reliability of cognitive assessment tool varies widely
7. Study identifies double-balloon enteroscopy as cost-effective approach for obscure GI bleeding
8. Health study in northern Uganda calls for improved services for internally displaced persons
9. Pregnancy study finds strong association between two antidepressants and heart anomalies
10. Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage
11. Study of ancient and modern plagues finds common features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... How big is ... facilities, and who are the most active developers? , In the first ... Real Estate Insights (HREI) found that outpatient medical real estate development projects totaling ...
(Date:3/29/2017)... ... 29, 2017 , ... The assembly of synthetic DNA has ... repetitive steps and often scientists require many different versions of DNA. Therefore, this ... in a lower error rate and cost saving for reagents and consumables. , ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... The Wharton ... WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to establish ... admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified Penn ...
(Date:3/28/2017)... , ... March 28, 2017 , ... For many women, getting birth control isn’t as ... , meaning they either don’t have access to a health care facility or a pharmacy ... remote regions of the United States or for many who are faced with health or ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... Varian Medical Systems (NYSE: VAR ) ... quarter of fiscal year 2017 following the close of regular ... be followed by a teleconference available to all interested parties ... to the conference call webcast will be available on the ... call and replay: ...
Breaking Medicine Technology: